<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(9)</volume><submitter>Hofman S</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Adverse childhood experiences contribute to the development of personality disorders (PDs). Although trauma-focused interventions are effective for posttraumatic stress disorder (PTSD), their effect on PD symptoms is less established.&lt;h4>Objective&lt;/h4>To evaluate the effectiveness of eye movement desensitization and reprocessing (EMDR) therapy in reducing PD symptoms compared with a waiting list, regardless of PTSD status.&lt;h4>Design, setting, and participants&lt;/h4>This 2-arm, multicenter, single-blind, randomized clinical trial was performed in the specialized outpatient departments of 2 clinics in the Netherlands from February 22, 2021, to October 2, 2024. Participants included 159 patients with PD diagnosed using the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). Data were analyzed based on intention to treat.&lt;h4>Intervention&lt;/h4>Ten 90-minute EMDR sessions for 5 weeks, targeting traumatic and adverse memories linked to PD symptoms.&lt;h4>Main outcomes and measures&lt;/h4>Pretreatment, posttreatment, and 3-month follow-up assessments using the Assessment of DSM-IV Personality Disorders (ADP-IV), SCID-5-PD, Level of Personality Functioning Scale (LPFS), and Difficulties in Emotion Regulation Scale (DERS).&lt;h4>Results&lt;/h4>Among the 159 patients included in the analysis, mean (SD) age was 35.4 (12.0) years, and 130 were female (81.8%). Seventy-nine participants were randomized to the EMDR group and 80 to the waiting-list control group. Four participants (5.1%) dropped out of the EMDR group, and 16 (20.3%) were early completers, without adverse events. EMDR therapy outperformed the waiting-list condition for ADP-IV post treatment (β, -37.93 [95% CI, -52.54 to -23.33]; P &lt; .001; Cohen d = 0.31 [95% CI, -0.05 to 0.66]) and at follow-up (β, -45.73 [95% CI, -64.90 to -26.56]; P &lt; .001; Cohen d = 0.46 [95% CI, 0.10-0.82]), SCID-5-PD post treatment (β, -3.65 [95% CI, -5.87 to -1.42]; P = .002; d = 0.48 [95% CI, 0.14-0.82]) and at follow-up (β, -3.70 [95% CI, -7.10 to -0.30]; P = .03; Cohen d = 0.61 [95% CI, 0.25-0.97]), LPFS post treatment (β, -3.13 [95% CI, -4.86 to -1.41]; P &lt; .001; Cohen d = 0.31 [95% CI, -0.05 to 0.67]) and at follow-up (β, -3.62 [95% CI, -5.96 to -1.28]; P = .003; Cohen d = 0.43 [95% CI, 0.06-0.79]), and DERS post treatment (β, -9.03 [95% CI, -14.90 to -3.15]; P = .003; Cohen d = 0.35 [95% CI, -0.01 to 0.71]) and at follow-up (β, -11.73 [95% CI, -19.90 to -3.55]; P = .005; Cohen d = 0.62 [95% CI, 0.25-0.98]). PD remission was more common in the EMDR than control groups both post treatment (ADP-IV, 38.3% vs 6.8%; SCID-5-PD, 33.3% vs 7.8%) and at follow-up (ADP-IV, 45.4% vs 5.9%; SCID-5-PD, 44.1% vs 15.8%).&lt;h4>Conclusions and relevance&lt;/h4>In this randomized clinical trial of 159 patients with PD, EMDR therapy led to significant reduction in PD symptoms, with 30 (44.1%) achieving remission. These findings support the potential of EMDR therapy for PD treatment and encourage further confirmatory research.&lt;h4>Trial registration&lt;/h4>Netherlands Trial Register: NL9078.</pubmed_abstract><journal>JAMA network open</journal><pagination>e2533421</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12464786</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Eye Movement Desensitization and Reprocessing Therapy in Persons With Personality Disorders: A Randomized Clinical Trial.</pubmed_title><pmcid>PMC12464786</pmcid><pubmed_authors>Slotema CW</pubmed_authors><pubmed_authors>de Jongh A</pubmed_authors><pubmed_authors>Hofman S</pubmed_authors><pubmed_authors>Hafkemeijer L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Eye Movement Desensitization and Reprocessing Therapy in Persons With Personality Disorders: A Randomized Clinical Trial.</name><description>&lt;h4>Importance&lt;/h4>Adverse childhood experiences contribute to the development of personality disorders (PDs). Although trauma-focused interventions are effective for posttraumatic stress disorder (PTSD), their effect on PD symptoms is less established.&lt;h4>Objective&lt;/h4>To evaluate the effectiveness of eye movement desensitization and reprocessing (EMDR) therapy in reducing PD symptoms compared with a waiting list, regardless of PTSD status.&lt;h4>Design, setting, and participants&lt;/h4>This 2-arm, multicenter, single-blind, randomized clinical trial was performed in the specialized outpatient departments of 2 clinics in the Netherlands from February 22, 2021, to October 2, 2024. Participants included 159 patients with PD diagnosed using the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). Data were analyzed based on intention to treat.&lt;h4>Intervention&lt;/h4>Ten 90-minute EMDR sessions for 5 weeks, targeting traumatic and adverse memories linked to PD symptoms.&lt;h4>Main outcomes and measures&lt;/h4>Pretreatment, posttreatment, and 3-month follow-up assessments using the Assessment of DSM-IV Personality Disorders (ADP-IV), SCID-5-PD, Level of Personality Functioning Scale (LPFS), and Difficulties in Emotion Regulation Scale (DERS).&lt;h4>Results&lt;/h4>Among the 159 patients included in the analysis, mean (SD) age was 35.4 (12.0) years, and 130 were female (81.8%). Seventy-nine participants were randomized to the EMDR group and 80 to the waiting-list control group. Four participants (5.1%) dropped out of the EMDR group, and 16 (20.3%) were early completers, without adverse events. EMDR therapy outperformed the waiting-list condition for ADP-IV post treatment (β, -37.93 [95% CI, -52.54 to -23.33]; P &lt; .001; Cohen d = 0.31 [95% CI, -0.05 to 0.66]) and at follow-up (β, -45.73 [95% CI, -64.90 to -26.56]; P &lt; .001; Cohen d = 0.46 [95% CI, 0.10-0.82]), SCID-5-PD post treatment (β, -3.65 [95% CI, -5.87 to -1.42]; P = .002; d = 0.48 [95% CI, 0.14-0.82]) and at follow-up (β, -3.70 [95% CI, -7.10 to -0.30]; P = .03; Cohen d = 0.61 [95% CI, 0.25-0.97]), LPFS post treatment (β, -3.13 [95% CI, -4.86 to -1.41]; P &lt; .001; Cohen d = 0.31 [95% CI, -0.05 to 0.67]) and at follow-up (β, -3.62 [95% CI, -5.96 to -1.28]; P = .003; Cohen d = 0.43 [95% CI, 0.06-0.79]), and DERS post treatment (β, -9.03 [95% CI, -14.90 to -3.15]; P = .003; Cohen d = 0.35 [95% CI, -0.01 to 0.71]) and at follow-up (β, -11.73 [95% CI, -19.90 to -3.55]; P = .005; Cohen d = 0.62 [95% CI, 0.25-0.98]). PD remission was more common in the EMDR than control groups both post treatment (ADP-IV, 38.3% vs 6.8%; SCID-5-PD, 33.3% vs 7.8%) and at follow-up (ADP-IV, 45.4% vs 5.9%; SCID-5-PD, 44.1% vs 15.8%).&lt;h4>Conclusions and relevance&lt;/h4>In this randomized clinical trial of 159 patients with PD, EMDR therapy led to significant reduction in PD symptoms, with 30 (44.1%) achieving remission. These findings support the potential of EMDR therapy for PD treatment and encourage further confirmatory research.&lt;h4>Trial registration&lt;/h4>Netherlands Trial Register: NL9078.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T21:06:27.007Z</modification><creation>2026-05-30T03:07:17.925Z</creation></dates><accession>S-EPMC12464786</accession><cross_references><pubmed>40996761</pubmed><doi>10.1001/jamanetworkopen.2025.33421</doi></cross_references></HashMap>